ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Panitumumab

Also written as “ABX-EGF”, “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab” and “Panitumumab (ABX-EGF)”.

Its studies are mostly in Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Colonic Neoplasms · Neoplasms · Squamous Cell Carcinoma of Head and Neck, led by 3 companies.

Drug pagePanitumumab: every studyAll 196 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 10, 200537 company-led studies, 2 open or runningNext primary completion: Sep 25, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgenits history only351 open or runningphase 3since Jun 10, 2005Apr 25, 2002Sep 25, 2028phase 3 · NCT06252649
Dr. Reddy's Laboratoriesits history only10 open or runningphase 4since Nov 24, 2014Nov 24, 2014none ahead
R-Pharm11 open or runningphase 1since Apr 14, 2026Apr 14, 2026none ahead

Also a collaborator on its studies: Takeda and Immunex.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of R-Pharm only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 14, 2026First study: phase 1 study in Colorectal NeoplasmsFirst studyNCT07543744 · 180 planned · Russia

TargetBeta

EGFR →read by rule
“A human IgG2kappa monoclonal antibody specific for the epidermal growth factor receptor (EGFR)”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

The one study R-Pharm leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07543744Colorectal Neoplasms · Russia1RecruitingMay 15, 2026180

How it is read

Names in the registry

  • “Panitumumab”, 29 entries
  • “ABX-EGF”, 5 entries
  • “oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab”, 3 entries
  • “Panitumumab (ABX-EGF)”, 2 entries
  • “RPH-030”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.